Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T93653
(Former ID: TTDI02353)
|
|||||
Target Name |
Cathepsin V (CTSV)
|
|||||
Synonyms |
UNQ268/PRO305; Cathepsin U; Cathepsin L2; CTSU; CTSL2; CATL2
Click to Show/Hide
|
|||||
Gene Name |
CTSV
|
|||||
Target Type |
Patented-recorded target
|
[1] | ||||
Disease | [+] 2 Target-related Diseases | + | ||||
1 | Bone cancer [ICD-11: 2B5Z] | |||||
2 | Chronic pain [ICD-11: MG30] | |||||
Function |
May have an important role in corneal physiology. Cysteine protease.
Click to Show/Hide
|
|||||
BioChemical Class |
Peptidase
|
|||||
UniProt ID | ||||||
EC Number |
EC 3.4.22.43
|
|||||
Sequence |
MNLSLVLAAFCLGIASAVPKFDQNLDTKWYQWKATHRRLYGANEEGWRRAVWEKNMKMIE
LHNGEYSQGKHGFTMAMNAFGDMTNEEFRQMMGCFRNQKFRKGKVFREPLFLDLPKSVDW RKKGYVTPVKNQKQCGSCWAFSATGALEGQMFRKTGKLVSLSEQNLVDCSRPQGNQGCNG GFMARAFQYVKENGGLDSEESYPYVAVDEICKYRPENSVANDTGFTVVAPGKEKALMKAV ATVGPISVAMDAGHSSFQFYKSGIYFEPDCSSKNLDHGVLVVGYGFEGANSNNSKYWLVK NSWGPEWGSNGYVKIAKDKNNHCGIATAASYPNV Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Patented Agent(s) | [+] 1 Patented Agents | + | ||||
1 | PMID27998201-Compound-12 | Drug Info | Patented | Cancer related pain | [1] | |
Mode of Action | [+] 1 Modes of Action | + | ||||
Inhibitor | [+] 2 Inhibitor drugs | + | ||||
1 | PMID27998201-Compound-12 | Drug Info | [1] | |||
2 | PMID21277783C7 | Drug Info | [2] |
Cell-based Target Expression Variations | Top | |||||
---|---|---|---|---|---|---|
Cell-based Target Expression Variations |
Drug Binding Sites of Target | Top | |||||
---|---|---|---|---|---|---|
Ligand Name: Nalpha-[(4-Methylpiperazin-1-Yl)carbonyl]-N-[(3s)-1-Phenyl-5-(Phenylsulfonyl)pentan-3-Yl]-L-Phenylalaninamide | Ligand Info | |||||
Structure Description | CRYSTAL STRUCTURE OF HUMAN CATHEPSIN V COMPLEXED WITH AN IRREVERSIBLE VINYL SULFONE INHIBITOR | PDB:1FH0 | ||||
Method | X-ray diffraction | Resolution | 1.60 Å | Mutation | Yes | [3] |
PDB Sequence |
LPKSVDWRKK
10 GYVTPVKNQK20 QCGSCWAFSA30 TGALEGQMFR40 KTGKLVSLSE50 QNLVDCSRPQ 60 GNQGCNGGFM70 ARAFQYVKEN80 GGLDSEESYP90 YVAVDEICKY100 RPENSVAQDT 110 GFTVVAPGKE119 KALMKAVATV129 GPISVAMDAG139 HSSFQFYKSG149 IYFEPDCSSK 159 NLDHGVLVVG169 YGFEGANSDN179 SKYWLVKNSW189 GPEWGSNGYV199 KIAKDKNNHC 209 GIATAASYPN219 V
|
|||||
|
GLN19
2.887
CYS22
4.618
GLY23
3.500
SER24
4.765
CYS25
1.793
TRP26
3.148
GLY61
3.738
GLN63
3.596
CYS65
3.457
ASN66
3.417
GLY67
3.126
GLY68
2.896
|
|||||
Click to View More Binding Site Information of This Target with Different Ligands |
Different Human System Profiles of Target | Top |
---|---|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Tissue Distribution
of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.
The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects
(Nat Rev Drug Discov, 20: 64-81, 2021).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Human Similarity Proteins
Human Tissue Distribution
Human Pathway Affiliation
|
Protein Name | Pfam ID | Percentage of Identity (%) | E value |
---|---|---|---|
Putative inactive cathepsin L-like protein CTSL3P (CTSL3P) | 61.818 (68/110) | 1.40E-36 |
Note:
If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.
|
KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
---|---|---|---|
Lysosome | hsa04142 | Affiliated Target |
|
Class: Cellular Processes => Transport and catabolism | Pathway Hierarchy | ||
Apoptosis | hsa04210 | Affiliated Target |
|
Class: Cellular Processes => Cell growth and death | Pathway Hierarchy |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Affiliated Biological Pathways | Top | |||||
---|---|---|---|---|---|---|
KEGG Pathway | [+] 1 KEGG Pathways | + | ||||
1 | Lysosome | |||||
Reactome | [+] 6 Reactome Pathways | + | ||||
1 | Endosomal/Vacuolar pathway | |||||
2 | Degradation of the extracellular matrix | |||||
3 | Activation of Matrix Metalloproteinases | |||||
4 | Trafficking and processing of endosomal TLR | |||||
5 | Assembly of collagen fibrils and other multimeric structures | |||||
6 | MHC class II antigen presentation | |||||
WikiPathways | [+] 1 WikiPathways | + | ||||
1 | Endochondral Ossification |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. | |||||
REF 2 | Acridone alkaloids as potent inhibitors of cathepsin V. Bioorg Med Chem. 2011 Feb 15;19(4):1477-81. | |||||
REF 3 | Crystal structure of human cathepsin V. Biochemistry. 2000 Oct 17;39(41):12543-51. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.